T
Tetsuya Mitsudomi
Researcher at Kindai University
Publications - 583
Citations - 51959
Tetsuya Mitsudomi is an academic researcher from Kindai University. The author has contributed to research in topics: Lung cancer & Epidermal growth factor receptor. The author has an hindex of 97, co-authored 541 publications receiving 46183 citations. Previous affiliations of Tetsuya Mitsudomi include University of Occupational and Environmental Health Japan & Gunma University.
Papers
More filters
Journal ArticleDOI
Effect of gefitinib on the survival of patients with recurrence of lung adenocarcinoma after surgery: a retrospective case-matching cohort study.
Tatsuya Katayama,Keitaro Matsuo,Takayuki Kosaka,Taijiro Sueda,Yasushi Yatabe,Tetsuya Mitsudomi +5 more
TL;DR: This study strongly suggested that gefitinib treatment improved OS of lung adenocarcinoma patients who had postoperative recurrence, especially those carrying EGFR mutations.
Journal ArticleDOI
Comparison of PD-L1 Expression Status between Pure-Solid Versus Part-Solid Lung Adenocarcinomas
Kenichi Suda,Masaki Shimoji,Shigeki Shimizu,Katsuaki Sato,Masato Chiba,Kenji Tomizawa,Toshiki Takemoto,Junichi Soh,Tetsuya Mitsudomi +8 more
TL;DR: LADs with GGO were correlated with a lower incidence of PD-L1 expression than pure-solid tumors, and this study included 124 patients with clinical T1a–c LAD who received pulmonary resections during 2007–2009.
Journal ArticleDOI
Adenocarcinoma and squamous cell carcinoma in the same lobe of the lung. A case report.
TL;DR: A 70-year-old man with double synchronous lung cancers in the right upper lobe, an adenocarcinoma and a squamous cell carcinoma is treated.
Journal Article
Clinical aspects of multimodality therapy for resectable locoregional esophageal cancer.
TL;DR: Concerns appear to be shifting to the question of whether definitive chemoradiation could be an alternative to surgery in the primary treatment of resectable locoregional esophageal cancer, and 2 randomized trials seem to show at first glance that definitive cheMoradiation can achieve results comparable to surgery with neoadjuvant chemorads.
Journal ArticleDOI
MA07.03 Alectinib (ALC) versus Crizotinib (CRZ) in ALK-Positive Non-Small Cell Lung Cancer (ALK+ NSCLC): Primary Results from Phase III Study (J-ALEX)
Young Hak Kim,Toyoaki Hida,Hiroshi Nokihara,Masashi Kondo,Koichi Azuma,Takashi Seto,Yuichi Takiguchi,Makoto Nishio,Hiroshige Yoshioka,Fumio Imamura,Katsuyuki Hotta,Satoshi Watanabe,Koichi Goto,Kazuhiko Nakagawa,Tetsuya Mitsudomi,Nobuyuki Yamamoto,Hiroshi Kuriki,Ryoichi Asabe,Tomohiro Tanaka,Tomohide Tamura +19 more